Mendel Money Management Has $1.07 Million Stake in Certara, Inc. (NASDAQ:CERT)

Mendel Money Management grew its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 120.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,565 shares of the company's stock after purchasing an additional 58,865 shares during the period. Mendel Money Management owned approximately 0.07% of Certara worth $1,065,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in CERT. Proficio Capital Partners LLC purchased a new stake in shares of Certara during the fourth quarter valued at approximately $148,000. Raymond James Financial Inc. acquired a new position in shares of Certara during the fourth quarter valued at $3,628,000. Thrivent Financial for Lutherans boosted its holdings in shares of Certara by 128.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 196,391 shares of the company's stock valued at $2,091,000 after acquiring an additional 110,481 shares during the period. Sei Investments Co. boosted its holdings in shares of Certara by 2.6% during the fourth quarter. Sei Investments Co. now owns 1,137,612 shares of the company's stock valued at $12,116,000 after acquiring an additional 28,809 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Certara during the fourth quarter valued at $276,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Price Performance

Certara stock traded up $0.11 during midday trading on Friday, hitting $11.09. The company's stock had a trading volume of 1,152,145 shares, compared to its average volume of 1,651,786. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. The stock's 50-day moving average price is $11.17 and its 200-day moving average price is $11.85. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $16.18. The company has a market capitalization of $1.80 billion, a PE ratio of -554.50 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 EPS. Analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Robert W. Baird boosted their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. KeyCorp reduced their price objective on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a report on Monday, July 14th. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Morgan Stanley assumed coverage on shares of Certara in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. Finally, Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $15.29.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.